Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380805 · ClinicalTrials.gov registry record · Phase 2
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
A Phase 2 study, sponsored by Akeso.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04380805 is a Phase 2 study that has completed, run by Akeso. The registered enrollment target is 30 participants.
The verdict
NCT04380805, a Phase 2 study, has completed, sponsored by Akeso.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.
Interventions
- BIOLOGICAL AK104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04380805
The ClinicalTrials.gov registry entry for NCT04380805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akeso, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AK104 is the first listed.
NCT04380805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04380805 about?
NCT04380805 is a clinical study titled "A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer". This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.
What is the current status of trial NCT04380805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-07-15. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04380805?
The interventions under investigation include: AK104 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04380805?
This trial is sponsored by Akeso, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.